Clinical trials: Dyslipidemias
Dyslipidemias, High Cholesterol
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Trial name
- ROSE (NCT04753606)
- Testing
- Obicetrapib
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia, Coronary Heart Disease
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
This is a multicenter, randomized, parallel group, placebo controlled study designed to evaluate the efficacy, safety, and tolerability of ezetimibe added to ongoing atorvastatin therapy compared with ongoing atorvastatin…
- Trial name
- NCT00202904
- Testing
- ezetimibe
- Volunteers
- 81 people
- Sponsor
- Organon and Co
Dyslipidaemia
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint…
- Trial name
- CEPHEUS (NCT01221584)
- Where
- 8 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Healthy, Hypercholesterolemia
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
The goal of this study is to learn what happens to different doses of enlicitide chloride over time in the body of healthy participants and participants taking statins, a group of medicines used to reduce the levels of high…
- Trial name
- NCT06655311
- Testing
- Enlicitide Chloride
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Metabolic Syndrome
Association of Genes to Resistance to Weight Loss in Obese Patients
The overall goal of this study is to determine whether variations in the perilipin, and several other, genes would be a useful tool for physicians who are caring for morbidly obese patients to guide therapy.
- Conditions
- Obesity, Metabolic Syndrome, Dyslipidemia
- Trial name
- NCT00858221
- Where
- United States
- Volunteers
- 824 people
- Sponsor
- Interleukin Genetics, Inc.
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD risk strata of the NCEP III guidelines to achieve…
- Trial name
- NCT00651014
- Testing
- Ezetimibe
- Volunteers
- 82 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia
Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00776321
- Testing
- Eprotirome
- Where
- Sweden
- Volunteers
- 142 people
- Sponsor
- Karo Bio AB
Hypercholesterolemia
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917644
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Coronary Syndrome
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS)…
- Trial name
- V-INCEPTION (NCT04873934)
- Testing
- Inclisiran
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia, Familial Hypercholesterolemia
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a…
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia
- Trial name
- NCT00705211
- Testing
- Ezetimibe, Ezetimibe + other lipid-lowering medication(s)
- Volunteers
- 1,794 people
- Sponsor
- Organon and Co
Medical Conditions to be Studied, Dyslipidemia
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD.
- Conditions
- Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
- Trial name
- NCT02993120
- Where
- 118 sites in United States
- Volunteers
- 5,006 people
- Sponsor
- Amgen
Overweight, Elevated Cholesterol
Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man
This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels…
- Trial name
- Lyzme5 (NCT01634646)
- Testing
- Lyzme5
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Jeff Golini
Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
- Trial name
- NCT06112327
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 116 people
- Sponsor
- Verve Therapeutics, Inc.
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
- Trial name
- NCT01342211
- Testing
- Statin, PF-04950615 (RN316), Satin
- Where
- 44 sites in United States, Canada
- Volunteers
- 93 people
- Sponsor
- Pfizer
Dyslipidemias
A Phase III Long Term Study of K-877 Extended Release Tablet
To investigate the safety and efficacy of K-877 Extended Release (ER) once daily for 52 weeks in the morning or evening in dyslipidema.The starting dose of the ER tablet will be 0.2 mg/day.
- Trial name
- NCT04716595
- Testing
- K-877 ER 0.2 mg/day morning administration (once daily), K-877 ER 0.2 mg/day evening administration (once daily)
- Where
- 14 sites in Japan
- Volunteers
- 121 people
- Sponsor
- Kowa Company, Ltd.
Coronary Artery Disease, Coronary Heart Disease
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal…
- Conditions
- Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
- Trial name
- FIRST (NCT00616772)
- Testing
- ABT-335, Atorvastatin
- Where
- 124 sites in United States
- Volunteers
- 682 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are…
- Trial name
- SPIRE-SI (NCT02135029)
- Testing
- Bococizumab (PF-04950615;RN316), Atorvastatin
- Where
- 40 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.